Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Tekcapital reports full-year turnaround, shares pop

(Sharecast News) - Tekcapital reported a sharp turnaround in its financial performance on Friday, posting a profit after tax of $19.2m for 2024, compared with a loss of $15.7m the prior year. The AIM-traded intellectual property investment group attributed the improvement to increased portfolio valuations and lower expenses, with administrative costs down 26% to $2m.

Net assets rose 46% to $70.1m, while portfolio valuation increased nearly 50% to $61.5m, driving the net asset value per share up 22% to 33 cents.

The year saw two portfolio companies - MicroSalt and GenIP - successfully listed on AIM, crystallising a combined $18.3m in value.

Four of Tekcapital's five portfolio companies were now publicly traded, with Guident preparing for a Nasdaq initial public offering in 2025.

Across the portfolio, businesses made significant commercial progress, including new contracts, strategic partnerships, and product launches.

MicroSalt secured recurring B2B orders from a global food manufacturer, while Innovative Eyewear expanded retail distribution.

GenIP entered the Saudi market and signed agreements across several regions, and Belluscura gained Medicare reimbursement eligibility in the US.

Tekcapital's share price rose 27% during the year, outperforming the AIM All-Share Index and its UK-listed IP commercialisation peers.

The company highlighted its relatively low operating cost base and its belief that the current 66% share price discount to net asset value was unjustified.

With a strengthened balance sheet, ongoing portfolio momentum, and plans to invest in generative AI technologies, Tekcapital said it was well-positioned for further growth and value creation in 2025.

"We are excited to provide this 2024 summary report which describes a few of our portfolio company achievements and their contribution to our profitability and growth," said executive chairman Dr Clifford Gross.

"In 2024 our net assets reached $70.1m, an increase of around 46%, over the previous year, an annual record since the company's inception.

"Net asset value per share was 33 cents."

Dr Gross said the firm's performance reflected strong commercial progress through the completion of two AIM listings - MicroSalt and GenIP - and as a result, four of its five portfolio companies were now listed.

"Additionally, we observed significant commercial traction for Innovative Eyewear as they achieved several new product and go-to-market milestones.

"We were also pleased to note MicroSalt has received new and follow-on B2B orders from a major snack food manufacturer.

"Further, we believe that Guident's commercial advancements, coupled with improving performance and market traction in the autonomous vehicle industry, have created a fertile opportunity for Tekcapital to potentially further crystallise its balance sheet in 2025."

Tekcapital believed that its success in 2024 was "a testament to its portfolio companies' strategic positioning and relevance", Clifford Gross added.

"Our core long-term financial objective is to grow net assets and returns on invested capital.

"Once material levels of capital are monetized from our portfolio companies, we will seek to provide a special dividend.

"We remain committed to this long-term objective, and our portfolio companies' progress in 2024 is a good step in that direction."

At 1328 BST, shares in Tekcapital were up 18.62% at 9.49p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Hunting reports higher margins, full-year earnings
(Sharecast News) - Hunting reported higher earnings and margins for 2025 on Thursday despite a modest decline in revenue, as the precision engineering group benefited from improved operational performance and continued to expand shareholder returns under its long-term growth strategy.
Ibstock earnings dip as expected in 'progressively tougher market'
(Sharecast News) - Building products manufacturer Ibstock reported a drop in full-year earnings on Thursday, in line with revised guidance, in a "progressively tougher market".
OSB hikes dividend, launches buyback after fall in profit
(Sharecast News) - OSB Group reported a decline in annual profit for 2025 on Thursday as higher administrative costs and an impairment charge weighed on earnings, though the specialist lender said loan growth and originations increased and it announced a £100m share buyback alongside a higher dividend.
Spire Healthcare grows annual profits, but NHS outlook uncertain in 2026
(Sharecast News) - Takeover target and Spire Healthcare reported a small rise in adjusted profits over 2025 which it hailed as a "resilient performance" against a backdrop of significant cost headwinds, though the outlook for 2026 was proving more uncertain due to a drop in NHS commissioning activity.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.